Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (11084)	3/31/2004 11:39:31 AM
From: Biomaven	Read Replies (2) \| Respond to of 52153

<MSHL> Not much of a trading stock, is it? It's a really weird setup. The float is minuscule and the sub is valued at more than the foreign parent. It's altogether quite unclear how (or even if) to play it. MSHL doesn't get much publicity in the US, but Novogen seems pretty aggressive PR-wise in Australia. These are pretty interesting Phase I results for a drug that has little or no toxicity. The dose-response in the one trial was a little weird - I don't understand why the lower doses would work better. Small warning flag, perhaps. But this isn't a traditional cytotoxic drug, so maybe we should expect a little weirdness. Peter